April 25, 2025 07:00 AM EDT
Peer Review

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Lei Lei Wu

News Reporter

When the board of Bel­gian biotech Gala­pa­gos asked Paul Stof­fels to be­come CEO, he told them he was on­ly in­ter­est­ed in do­ing the job for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

Ab­b­Vie's im­munol­o­gy fran­chise re­mains a pow­er­house, as Skyrizi, Rin­voq com­bine for $5B

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times